Drug Trial Radar · NCT07824167
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 8 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy. It is given to help prevent severe RSV illness. This study will measure clesrovimab and other RSV antibodies in infants' blood and noses to learn how much of the drug reaches the nose, how long the antibodies remain, and how antibody levels change if an infant becomes infected with RSV.
Conditions
- RSV Infection
Interventions
ClesrovimabBiological
Clesrovimab (ENFLONSIA™) is a commercially available product that is administered as part of standard-of-care RSV prevention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean concentration (GMC) of serum RSV pre-fusion (preF) binding IgG antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
- Geometric mean concentration (GMC) of nasal RSV pre-fusion (preF) binding IgG antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
- Geometric mean titers (GMT) of serum RSV-A neutralizing antibodiesTime frame: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory Children's Center-Vaccine Research Clinic
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.